The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...

New Hyde Park, N.Y.-based Northwell Health has opened a $5.3 million digestive health center in Uniondale, N.Y., according to a March 20 report from Long Island Business News. The new center is a part ...

The following is a summary of "Worsening disease severity as measured by I-SEE associates with decreased treatment response ...

Researchers conducted a large-scale online survey of clinicians in the Asia-Pacific region to investigate treatment policies for the gastric cancer-causing bacteria Helicobacter pylori.

Helicobacter pylori bacteria is considered to be the main cause of gastric cancer, with the infection rate particularly high ...

PR Newswire DENVER Recent clinical data demonstrate how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression ...